Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGG and BB-12 in newly diagnosed type 1 diabetes
NCT03032354Phase 4Unknown
- Sponsor
- Medical University of Warsaw
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 4, randomised, double-blind trial of Lactobacillus rhamnosus GG and bifidobacterium animalis subsp. lactis bb-12 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Medical University of Warsaw. Primary endpoint: Area under the curve of C-peptide level at 12 months. Status: unknown.
02
Drugs
Lactobacillus rhamnosus GGbifidobacterium animalis subsp. lactis bb-12
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03032354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032354.